← Back to news
August 25, 2026
Trump's FDA Nominee Could Intensify Scrutiny on Abortion Drug Mifepristone
- John Mize, CEO of Americans United for Life, supports Overton's nomination, citing her pro-life stance.
- Overton's confirmation could result in renewed safety reviews of mifepristone, which has a boxed warning for serious risks.
- Mize anticipates tighter restrictions on mifepristone, potentially reinstating in-person doctor visits for prescriptions.
Read the news this way every day.
Concur organizes political reporting into clear stories and shows the sources behind each one.
Free. No ads.
2 Sources
- The Movement: MAHA and anti-abortion groups split on FDA nomineeAug 25, 2026 at 12:00 PM · The Hill
- Pro-life CEO predicts Trump FDA nominee could bring renewed scrutiny to abortion drug risksAug 25, 2026 at 5:38 PM · Fox News